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and post-year) retrospective cohort design, adherence of patients who enrolled in 
traditional managed care plans in the pre-year but changed to full replacement CDHPs 
in the post-year was compared to that of patients who continuously enrolled in tra-
ditional plan. Adherence was measured in four ways: 1) post-year continuation rate, 
and among continuous users; 2) gap between the last reﬁll of the pre-year and the ﬁrst 
reﬁll in the post-year; 3) change of compliance rate from the pre- to the post-year; 
and 4) total days with continuous drug supply in the post-year. Analysis was con-
ducted on eight drug classes: asthma, cardiac, diabetes, epilepsy, hypertension, hyper-
lipidemia, rheumatoid arthritis, and thyroid, that were identiﬁed from Speciﬁc 
Therapeutic Classiﬁcation code. RESULTS: CDHP patients had a slightly higher 
illness burden and used more medication in the pre-year. Continuation rate in the 
post-year was relatively high for all drug classes though the CDHP patients were less 
likely continue for cardiac and cholesterol drugs. Among continuous patients, CDHP 
patients took slightly longer to reﬁll their ﬁrst prescription in the post-year for four 
drug classes (4 days longer for cardiac and hypertension drugs, 5 days longer for 
cholesterol and 3 days longer for thyroid drugs). Compliance rate dropped overtime 
in both cohorts but the reduction was bigger among CDHP patients for three drug 
classes (adjusted ratio of odds ratios was 0.77, 0.78, 0.69 for asthma, cardiac, and 
cholesterol drugs, respectively). CDHP patients also terminated their continuous drug 
supply earlier (21 days earlier for epilepsy and 27 days earlier cholesterol drugs, 
respectively). CONCLUSIONS: Adherence was lower in a few drug classes among 
patients who enrolled in consumer-driven health plans.
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OBJECTIVES: To assess the medication usage behaviour of prescription drugs and 
study self medication behaviour in outdoor patients. METHODS: A prospective 
observational study was performed in outpatient pharmacy at a public teaching 
hospital in Northern India. Patients more than 18 years and who could speak, write 
or read Hindi or English were included. Hearing and visually disabled patients were 
excluded. The medication usage behaviour, drug knowledge, adherence to prescribed 
medication and self medication behaviour were assessed using a structured and vali-
dated questionnaire using Cronbach Alpha. RESULTS: A total of 160 patients were 
assessed. The median age was 38 years. The most common problems identiﬁed 
involved awareness about the name and frequency of the drugs prescribed (39%), 
discontinuation of the medication without consultation (38%), unaware of proper 
storage of medicines (48%), knowledge about allergies (32%), and side effects (18%) 
of the drugs prescribed. Interestingly, it was observed that 90% of the patients had 
an understanding of their disease(s) diagnosed. Patients maintained regular follow up 
with the physician (88%) and consulted physician/pharmacist in case of an unpleasant/ 
alarming drug effect (77%). Majority of the patients (61%) used ayurvedic/homeo-
pathic preparations in conjunction with prescribed allopathic medicines. More than 
three fourths of the patients (82%) self medicated using herbals and other dietary 
supplements for their illness. OTC medication use (85%) was seen for common indica-
tions such as fever, cough, headache and bodyache. CONCLUSIONS: Based upon 
these ﬁndings, it is clear that improvement in medication usage behaviour requires 
counseling to the patients in the identiﬁed areas.
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OBJECTIVES: We assessed the quality and characteristics of pharmacoeconomic 
evaluation submitted for reimbursement since Korean positive list system introduction. 
METHODS: Twenty-four submissions with pharmacoeconomic evaluation (PE) were 
included in this study, which are new medicines evaluated by Drug Beneﬁt Coverage 
Assessment Committee (DBCAC) from introduction of positive list system to June 30th 
in 2009. We evaluated them with HIRA PE checklist consisted of 21 items which 
was developed for assessing the appropriateness according to the guideline of phar-
macoeconomic evaluation in Korea and QHES checklist. RESULTS: Twenty-four 
submissions were categorized as Cost-Minimization analysis (n = 16, 66.6%), Cost-
Effectiveness analysis (n = 4, 16.7%) and Cost-Utility analysis (n = 4, 16.7%). On the 
average, 15 among 21 items of HIRA PE checklist were fulﬁlled (73%, range 
52.4∼100%) and quality assessment score by QHES was 62.1 (range 31–97). The 
items which submissions mostly followed were presenting analysis perspective, disag-
gregated incremental cost-effectiveness ratio, appropriate selection of primary 
outcome and discount rate of cost and effectiveness. The issues noted as inadequate 
submissions were obscure search process of cost and effectiveness data, cost estima-
tion, insufﬁcient examination of uncertainty and generalizability. The range of ICER 
per QALY (n = 4) was showed from 8K to 59K USD. DBCAC didn’t evaluate cost-
effectiveness with explicit threshold values and decisions considering ICER were made 
by deliberating on the uncertainty surrounding them as well as disease severity, societal 
burden, quality of life, and innovative nature of the medicine. CONCLUSIONS: This 
study could be helpful for understanding present state of pharmacoeconomic evalua-
tion submitted since the introduction of Korean positive list system and valuable for 
suggesting items required to be improved for appraisal.
PHP59
PHARMACY BENEFIT INTEGRATION AND ADHERENCE TO EVIDENCE-
BASED MEDICINE IN A COMMERCIALLY-INSURED POPULATION
Bunz TJ, Nguyen HV
CIGNA, Bloomﬁeld, CT, USA
OBJECTIVES: The purpose of this analysis was to determine if integration of phar-
macy beneﬁts had an impact on the number of gaps in evidence-based care experienced 
by individuals and the number of gaps in care that those individuals close. METHODS: 
Database analysis was conducted on 262,000 individuals with coverage in 2008. 
Participants had to have 12 months of continuous enrollment in order to be included 
in the analysis. Matching on age, gender, and health risk was completed to partially 
adjust for differences between integrated and carve-out employers. A two-part regres-
sion model was then used to identify differences in the likelihood that individuals 
would adhere to evidence-based standards, and in the number of gaps in care that 
they would experience, while controlling for additional factors such as participation 
in outreach programs and plan design. RESULTS: Participants with integrated phar-
macy beneﬁts had a higher rate of gaps in care (Odds ratio 1.04, 95% ci 1.014–1.064), 
although the numbers of gaps experienced were lower (4.78 [95% ci 4.77–4.81] vs. 
4.87 [95% ci 4.85–4.89] in integrated plans vs. carve-out). While controlling for the 
initial number of open gaps, the likelihood of gap closure was higher in integrated 
plans than in carve-outs (Odds ratio 1.028 [95% ci 1.003–1.054]). The number of 
gaps closed was also higher (2.13 [95% ci 2.13–2.13] vs. 2.01 [95% ci 2.01–2.01] in 
integrated vs. carve-out). CONCLUSIONS: Higher rates of evidence-based gap closure 
are associated with individuals that participate in health plans with integrated phar-
macy beneﬁts when compared to individuals with carved-out plans.
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OBJECTIVES: Develop an essential medicines list (EML) in 2000 to improve rational 
use of medicines and contain costs in Middle East- Palestine. METHODS: We exam-
ined effects of the EML in the Palestinian health care public sector. We obtained data 
on prescription patterns for medicines from 3570 prescriptions given during outpatient 
visits in 17 health care facilities in the West Bank from 1997 to 2003. We analyzed 
the prescriptions to measure rational use. We modeled indicators of rational use as a 
function of the EML and 16 health center indicator variables. RESULTS: The 
EML was effective in shifting all prescribing indicators toward standard values. To 
improve rational medicine use, treatment protocols for the most common diseases and 
continuous education for medical staff is required. CONCLUSIONS: Treatment pro-
tocols that limit physicians’ prescription choices for the most common diseases are 
necessary to improve the rational use of medicines in any setting. We found that the 
prescribing indicators least affected were the number of medicines per encounter and 
antibiotics as a percent of all medicines prescribed. The most affected indicator was 
the injectable medicines as a percent of all prescribed medicines. While change in the 
use of injectable medicines may be related to changes in individual preferences, cultural 
beliefs and values, most of the patients were aware of the implementation of EML, 
since their medicines where changed and substituted with less expensive bioequivalent 
ones.
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BACKGROUND: Quantifying the value of pharmacist-provided services beyond dis-
pensing is imperative for the profession of pharmacy as it works to establish a baili-
wick within the evolving health care system. To date, the preponderance of research 
assessing the value of pharmacist-provided services takes a health care payer’s perspec-
tive. Less is known about the value consumers place on these services. The contingent 
valuation, or willingness-to-pay, method has been proposed as a technique to obtain 
consumer valuation of pharmacist-provided services. OBJECTIVES: The purpose of 
this research is to identify all published studies using the contingent valuation method 
to value pharmacist-provided services and evaluate those studies against published 
criteria for conducing contingent valuation surveys. METHODS: Relevant studies 
published in the English language were identiﬁed searching MEDLINE, ECONLIT 
and International Pharmaceutical Abstracts databases through December, 2008. Only 
studies that speciﬁcally elicited willingness-to-pay from actual or potential consumers 
of community pharmacist provided services were included. RESULTS: Twenty-three 
studies were identiﬁed using the search strategy outlined. Eighteen pharmacist-pro-
vided services were assessed in a variety of demographic and geographic populations. 
Studies were appraised using the 1993 NOAA panel recommendations for the contin-
gent valuation method. Not surprisingly, studies published before 1999 tended to use 
less standardized methods and typically did not conform to NOAA panel recommen-
dations, whereas those published after 1999 tended to have greater methodologic and 
statistical rigor. CONCLUSIONS: Surprisingly few published studies have employed 
the contingent valuation method to assess consumers’ perceptions of pharmacist-
provided services. Improving the quantity and quality of such studies will aid the 
profession in marketing pharmacy services to consumers. Understanding the pharmacy 
services that consumer’s value and their willingness-to-pay for those services will be 
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crucial as the profession continues to work toward establishing a sustainable and 
economically viable role within the dynamic health care system.
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OBJECTIVES: Programs to increase medication adherence are receiving increased 
attention. One incentive for pharmacies to implement such services is the potential 
increase in revenue. The objective was to estimate changes in revenue a community 
pharmacy during the ﬁrst three years after implementing a new medication manage-
ment service (RxSync ServiceSM). METHODS: A Markov economic model was devel-
oped using Excel. Model inputs are average week day/weekend patient volumes, 
current average medication possession ratio (MPR) for chronic medication prescrip-
tions, expected MPR for patients enrolled in the service, goals for enrolling existing 
and new patients into the service, current gross prescription sales, and net proﬁt on 
prescription sales. A three year time frame was used to estimate yearly increases in 
net revenue and monthly patient enrollment and increases in prescription volume. 
Model assumptions are based on data collected from ﬁve pharmacies participating in 
a project with the RxSync ServiceSM. RESULTS: A conservative scenario (70% of 
current target patients in 18 months) resulted in a peak of 414 additional prescriptions/
month at month 30 and increases in net revenue of $2956, $8415, and $9490 for the 
ﬁrst 3 years. An aggressive scenario (12 months) resulted in a peak of 414 additional 
prescriptions/month at month 21 and net revenue increases of $4896, $9364, and 
$9531. Adding a goal of 200 new patients, starting at month 6 and ﬁnishing 12 
months later resulted in a peak of 1,208 new prescriptions/month at month 21 and 
net revenue increases of $8,438, $26,386, $27,806. CONCLUSIONS: The model 
demonstrates that an effective medication adherence management program can 
increase net revenue for a community pharmacy. The increases will be relatively small 
the ﬁrst year of implementation unless a fairly aggressive recruitment strategy is used. 
If economic factors are importing when starting the service, recruitment of new 
patients should be a high priority in the implementation strategy.
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OBJECTIVES: Adverse drug reactions (ADRs) accounts for increased morbidity, mor-
tality, and have a signiﬁcant impact on health care cost. This study was planned to 
assess the incidence and pattern of ADRs among hospitalized patients in nephrology 
department and to estimate the direct cost attributable to ADRs. METHODS: This 
was a prospective surveillance study which included all patients admitted to nephrol-
ogy department of tertiary care hospital within eight months period. Patients were 
monitored from the day of admission till the day of discharge for the occurrence and 
reporting of ADRs through intensive monitoring by investigator (clinical pharmacist) 
and spontaneous reporting by health care professionals. ADRs reported were analysed 
for various parameters. RESULTS: Out of 259 hospitalized patients, 58 patients 
developed 94 ADRs with an overall incidence of 22.39%. In 23 (8.88%) patients, 
ADR was present at the time of hospital admission which accounted for 34 ADRs 
(36.17%). In 3.86% of patients, it was the reason for hospital admission. Drug class 
most commonly implicated in the ADRs was immunosuppressive agents (45.74%). 
Type A reactions (93.61%) were more common among patients. Upon causality 
assessment, majority (53.19%) of the reactions were possible in nature and majority 
(58.51%) was found to be of moderate severity. Total cost attributed to ADRs was 
estimated to be Rs 92,019 and average cost incurred for a patient for managing ADR 
was Rs 1,586.53. CONCLUSIONS: Adverse drug reactions occurred commonly in 
hospitalized patients in nephrology ward. Vigilant monitoring of drugs most com-
monly implicated in ADRs in nephrology ward like immunosuppressive agents is of 
utmost importance to avoid extra cost incurred.
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OBJECTIVES: The federal government provided approximately $29 million from 
2003–2007 to help states establish and maintain prescription drug monitoring pro-
grams (PDMPs) aimed at reducing diversion and abuse of pharmaceuticals. The 
objective of this study is to compare aggregated prescription drug-related mortality 
rates in states with active PDMPs compared to states with inactive PDMPs. 
METHODS: Data on ten states with prescription drug-related mortality rates are 
available from the Drug Abuse Warning Network (DAWN). As of 2007, 6 states had 
active PDMPs: Maine, Massachusetts, New Mexico, Oklahoma, Utah and Virginia. 
Whereas four states had inactive PDMPs: Maryland, New Hampshire, Oregon and 
Vermont. Independent samples t-test was used to determine signiﬁcance (p = 0.10) in 
mean mortality rates between active and inactive PDMPs. RESULTS: Among the 10 
states, 4454 drug-related deaths were reported in 2007. States with active PDMPs 
received a mean of $908,756 compared to $287,056 for states with inactive PDMPs. 
Among states with active PDMPs, New Mexico had the highest drug-related mortality 
rate (21.0%) and among states with inactive PDMPs, Maryland had the highest 
mortality rate (14.6%). A t-test showed no signiﬁcant difference (p = 0.37) in mean 
± SD drug-related death rate per 100,000 people associated with active PDMPs (14.2 
± 5.4) compared to states with inactive PDMPs (11.9 ± 2.2). CONCLUSIONS: Drug-
related mortality rates were lower in states with inactive programs, when compared 
to states with active PDMPs. This result may be representative of political pressure to 
enact programs in states with higher mortality rates. Although the sample size repre-
sents 20% of states, results should be viewed with caution. PDMPs are designed to 
decrease diversion and abuse, as well as associated morbidity and mortality; however 
more research is needed to determine their effectiveness and to devise ways to maxi-
mize their utility.
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OBJECTIVES: Evaluate the useffulness of cost per DDD to identify problematic drugs 
in medium- and high-level complexity hospitals from Colombia. METHODS: This 
was a cross-sectional study where drug prescriptions were evaluated in 331 second- 
and third-level complexity hospitals from 27 Colombian departments during 2006–
2007. RESULTS: A total of 38,863 prescriptions for 3663 patients were analyzed; 
54.7% of them patients afﬁliated to contributory health care system. The medication 
consumption was of 8, 39 daily deﬁned doses (DDD)/1000 patients. Filgastrim and 
Interferon represent almost 48% of DDDs of DU90%. The overall cost per DDD was 
US$3.9, being this cost lower in drugs of DU90% than drug out of this list (US$1.79 
vs.US$10.24, p = 0.03). Also the cost per DDD was higher in patients afﬁliated to 
contributory health care system than patients afﬁliated to public health care system 
(US$ 3.01 vs. US$2.09, p = 0.03). The antineoplastic and immunomodulating agents 
(Code L, ATC Classiﬁcation System), and drugs of musculoskeletal system (Code M, 
ATC Classiﬁcation System) were the drugs with higher cost per DDD (US$ 1686 and 
US$8.9, respectively). CONCLUSIONS: In this population, antineoplastic and immu-
nomodulating agents have cost per DDD that were 100 times higher than other drugs, 
also the estimation of cost per DDD allows identifying problematic drugs in this 
population such as Filgastrim and Interferon which prescriptions must be check care-
fully. Were evident differences of drug’s cost by type of health care system regardless 
that do not exist differences of drugs coverage in the Colombian health system by 
afﬁliation. The cost per DDD and DU 90% are useful indicators to identify problem-
atic drugs in developing countries.
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OBJECTIVES: To calculate the incidence of medication errors (MEs), examine types 
and causes of MEs, and estimate the excess hospital costs attributable to MEs during 
hospitalization. METHODS: The study population included patients who were hos-
pitalized in the medical/surgical units of two hospitals (176-bed community and 
417-bed academic hospitals) from January 2005-December 2006. ME data was col-
lected from hospital-speciﬁc voluntary reports for patients who experienced MEs. 
Hospital costs data was obtained from hospitals’ accounting department and were 
estimated from the payers’ point of view. The excess hospital costs if MEs were 
prevented in patients with MEs were estimated using a recycled prediction method. A 
generalized linear model with gamma distribution and log link function was used to 
derive coefﬁcients of the study variables from all patients. Among the patients with 
ME, the mean cost was predicted using the coefﬁcients derived from all patients, with 
the assumption that patients without MEs. All costs were converted to 2008 US 
dollars. RESULTS: A total of 470 MEs out of 57,554 patients were identiﬁed. The 
overall rate for MEs was 0.8 errors per 100 admissions and 1.7 errors per 1000 
patient-hospitalized days (harmful MEs = 0.4 and non-harmful MEs = 1.3). MEs 
occurred most frequently in the stage of administration(35.7%), followed by transcrip-
tion(25.7%), dispensing(18.5%), and ordering(15.5%). The most common types of 
MEs were wrong time (19.8%), wrong medication (18.1%), and wrong dose (17.0%). 
About 45% of MEs involved antibiotics, opiates, insulin, and electrolytes and ﬂuid. 
If patients who experienced MEs during hospitalization were not to have these MEs, 
their hospital costs would be reduced by $6,973 (95%CI US$6,138–7,808). CON-
CLUSIONS: This study demonstrated the importance of reducing medication errors 
because of its substantial economic burden to our society. Additional studies are 
needed to assess the cost effectiveness of various strategies in reducing MEs.
